OlympiA adjuvant trial results show olaparib for BRCA 1/2 mutated and high-risk early breast cancer reduced recurrence risk by 42%
Sanofi partnering with leading academic cooperative groups to study amcenestrant in the adjuvant setting for patients with estrogen receptor positive breast cancer
First results of the European AURORA study: towards a better understanding of the molecular changes driving metastatic breast cancer
First results of MA.32 trial: Common diabetes drug not effective against early-stage breast cancer, landmark trial reveals